Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)

Phase 1 Completed 11 enrolled Merck Sharp & Dohme LLC Ariad Pharmaceuticals · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

A Phase I, open-label, non-randomized, sequential dose escalation cohort trial of the safety, tolerability, and maximum tolerated dose (MTD) of AP23573 when administered intravenously as a 30-minute infusion, once daily for five days, repeated every two weeks, to patients with progressive or recurrent malignant glioma.

Timeline

Start: 2004-07
Primary completion: 2005-11
Completion: 2005-11

Publications

Results Reardon DA, Wen PY, Alfred Yung WK, Berk L, Narasimhan N, Turner CD, Clackson T, Rivera VM, Vogelbaum MA. Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial. Cancer Chemother Pharmacol. 2012 Apr;69(4):849-60. doi: 10.1007/s00280-011-1773-y. Epub 2011 Oct 30.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ridaforolimus	Small molecule	12.5 mg	Intravenous
Subject	ridaforolimus	Small molecule	15 mg	Intravenous

Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)

Summary

Timeline

Publications

Drugs

Indications